Kehrer J P
Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas, Austin 78712-1074.
Toxicology. 1989 Jul 3;57(1):69-82. doi: 10.1016/0300-483x(89)90035-8.
The clinical use of several anticancer drugs, including bleomycin and cyclophosphamide (CP), is often associated with lung damage which progresses to fibrosis. The effect of existing lung damage on the toxicity of these agents has not been investigated. Male BALB/c mice were treated intraperitoneally with 400 mg/kg butylated hydroxytoluene (BHT), 100 mg/kg CP or 100 mg/kg bleomycin, alone or in combination. Based on analyses of pulmonary DNA synthesis, each agent alone elicited significant lung damage with cell proliferation, peaking on Day 4 for BHT, Day 7 for CP and Day 14 for bleomycin. Quantitatively, the BHT lesion was greater than CP which was much greater than bleomycin. Mice given 100, 75, 50, 40 or 25 mg/kg bleomycin 1 day after BHT exhibited 100, 90, 22, 20 and 21% mortality, respectively. Treatment with 100, 50, 40 or 25 mg/kg CP 1 day after BHT resulted in 100, 54, 33 and 0% mortality, respectively. No mice treated with BHT, bleomycin or CP alone died. Total lung hydroxyproline content, an index of fibrosis, was significantly increased 14 days after the initial treatment in mice given BHT and 50 mg/kg bleomycin compared to mice treated with BHT, bleomycin or vehicle alone. Mice treated with 50 mg/kg CP 1 day after BHT did not develop fibrosis in excess of that attributable to the BHT alone. Treatment of mice with 100 mg/kg CP followed 1 or 2 days later by 100 mg/kg bleomycin resulted in 20-40% mortality, but no increase in lung hydroxyproline content compared to CP alone. Bleomycin delayed the onset of lung cell proliferation normally seen after treatment with BHT while CP attenuated this cell division only after it had begun. Treatments involving BHT and bleomycin did not alter lung sulfhydryl content. These data indicate that overall toxicity is increased in mice pretreated with BHT and then given bleomycin or CP while lung injury is enhanced only after bleomycin. The mechanism of the interaction with bleomycin is not known but may be related to a rapid inhibition of lung repair and not to oxidative stress.
包括博来霉素和环磷酰胺(CP)在内的几种抗癌药物在临床使用时,常常会导致肺损伤并进而发展为肺纤维化。现有的肺损伤对这些药物毒性的影响尚未得到研究。将雄性BALB/c小鼠腹腔注射400mg/kg丁基羟基甲苯(BHT)、100mg/kg CP或100mg/kg博来霉素,单独给药或联合给药。基于对肺DNA合成的分析,每种药物单独使用时都会引发显著的肺损伤并伴有细胞增殖,BHT在第4天达到峰值,CP在第7天达到峰值,博来霉素在第14天达到峰值。从数量上看,BHT引起的损伤大于CP,而CP引起的损伤又远大于博来霉素。在BHT给药1天后给予100、75、50、40或25mg/kg博来霉素的小鼠,死亡率分别为100%、90%、22%、20%和21%。在BHT给药1天后给予100、50、40或25mg/kg CP的小鼠,死亡率分别为100%、54%、33%和0%。单独给予BHT、博来霉素或CP的小鼠均未死亡。与单独给予BHT、博来霉素或赋形剂的小鼠相比,在最初治疗14天后,给予BHT和50mg/kg博来霉素的小鼠肺羟脯氨酸总量(纤维化指标)显著增加。在BHT给药1天后给予50mg/kg CP的小鼠,其纤维化程度并未超过单独给予BHT时的程度。先给予100mg/kg CP,1或2天后再给予100mg/kg博来霉素的小鼠,死亡率为20 - 40%,但与单独给予CP相比,肺羟脯氨酸含量并未增加。博来霉素延迟了BHT治疗后通常出现的肺细胞增殖的起始时间,而CP仅在细胞分裂开始后才减弱这种细胞分裂。涉及BHT和博来霉素的治疗并未改变肺巯基含量。这些数据表明,先用BHT预处理然后给予博来霉素或CP的小鼠总体毒性增加,而仅在给予博来霉素后肺损伤才会加重。与博来霉素相互作用的机制尚不清楚,但可能与肺修复的快速抑制有关,而非氧化应激。